Mylan says it will launch $27.14B bid for Perrigo


Save Story
Leer en español

Estimated read time: 1-2 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) — Dutch drugmaker Mylan says it will launch a $27.14 billion offer for Irish generic drug and ingredients maker Perrigo next Monday.

Perrigo has already turned down several offers from Mylan, so Mylan said Tuesday that it will take the latest offer directly to the company's shareholders. Perrigo said in August that it was confident its shareholders would reject Mylan's overture.

Mylan is offering $75 in cash and 2.3 shares of its own stock for every Perrigo share. Based on Friday's closing prices, that values Perrigo at about $185.52 per share, a premium of about 4 percent. Perrigo Co. stock added $1.85 to $180.65 on Tuesday.

Dublin-based Perrigo did not immediately comment on Mylan's announcement.

Mylan wants to combine its prescription generic drug business with Perrigo's business in over-the-counter products like vitamins, nutritional products and infant formula, and it says the two companies would have about $15 billion in combined annual revenue. Mylan shareholders voted in favor of the acquisition last month and European Union regulators have cleared it.

Mylan NV offered to buy Perrigo for $205 per share in April and later increased its offer to $232.23 per share, or $34.1 billion. Perrigo said that cash-and-stock offer wasn't worth as much as Mylan said. At the time Mylan's stock price was elevated as an even larger generic drug company, Teva Pharmaceutical Industries Ltd., was trying to buy Mylan. Mylan fended off Teva, which decided to buy Allergan PLC's generic drug business for $40.5 billion instead.

Shares of Mylan traded as high as $76.68 in April and closed at $48.05 on Friday. They fell about 15 percent on the day that Teva's offer for the Allergan generic unit was announced.

Mylan stock rose 67 cents to $48.72 on Tuesday.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.
    Newsletter Signup

    KSL Weather Forecast

    KSL Weather Forecast
    Play button